Further experiments showed that cryptotanshinone downregulates p300 expression, inhibits p300-mediated p-STAT3, and inhibits the mRNA level of Th17 cells and ROR-γt, a key transcription factor in the differentiation of Th17 cells, and regulates Th17/Treg imbalance (210), Thus, cryptotanshinone represents a potential immunomodulator for RA therapy. The gene discussed is EP300; the disease is rheumatoid arthritis.